Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy-induced nausea and vomiting (RINV): CTRI/2022/01/039723. PNQ ≥D 3 months after end of PTX 32.0% ...

Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with chemoradiotherapy for ...

Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...

MADRID, Aug. 31, 2025 /PRNewswire/ --Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously ...

At 3 months, in the COMFORT 2 Active Arm, there was an 80% responder rate where responders achieved at least 50% pain relief, and there was an average pain reduction of 66% (p<0.001) compared to a 4% ...